Arcturus Therapeutics Holdings Inc. filings document the regulatory record for a Nasdaq-listed commercial mRNA medicines and vaccines company with common stock registered under the symbol ARCT. Its Form 8-K reports furnish quarterly and annual financial results, corporate updates, Regulation FD presentations, and clinical or product disclosures tied to programs such as LUNAR-CF and KOSTAIVE.
The company’s proxy materials describe annual meeting matters, director elections, executive compensation, governance practices, and stockholder voting procedures. Other filings cover officer and board changes, registered security details, reporting-status notices such as Form 12b-25 notifications, and risk, capital-structure, collaboration, and development-stage disclosure relevant to its RNA therapeutics and vaccine business.
Arcturus Therapeutics Holdings Inc. director Moncef Slaoui received a grant of stock options as part of annual board compensation. The award covers 15,000 options for Common Stock at an exercise price of $7.30 per share, expiring on June 5, 2036. These options vest monthly over one year from the grant date, and following this grant he holds 15,000 derivative securities directly.
Arcturus Therapeutics Holdings Inc. director Magda Marquet received a grant of stock options covering 15,000 shares of common stock, with an exercise price of $7.30 per share and an expiration date of June 5, 2036. The options vest monthly over one year from the grant date and represent her 2026 annual grant as a member of the company’s Board of Directors.
Arcturus Therapeutics Holdings Inc. reported that director Jing L. Marantz received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $7.30 per share and expire on June 5, 2036.
According to the disclosure, these options represent Dr. Marantz’s 2026 annual grant for service on the Board of Directors. The shares underlying the option vest monthly over one year from the grant date, and following this award she holds stock options for 15,000 shares directly.
Arcturus Therapeutics Holdings Inc. reported the results of its 2026 annual meeting of stockholders. A quorum was present, with 21,435,189 shares represented out of 28,423,069 shares entitled to vote. Stockholders elected eight directors, each receiving more than 15.5 million votes in favor and remaining in office until the 2027 annual meeting. They also approved, on a non-binding advisory basis, the company’s named executive officer compensation, with 15,254,240 votes for and 327,647 against. In addition, stockholders ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 21,378,017 votes for and minimal opposition.
Arcturus Therapeutics Holdings Inc. reported that its Chief Financial Officer, Dennis Mulroy, received a grant of employee stock options covering 100,000 shares of common stock. These options have an exercise price of $8.63 per share and expire on May 1, 2036.
The grant was made under the company’s Amended and Restated 2019 Omnibus Equity Incentive Plan as part of equity compensation. The underlying shares vest 25% on May 1, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months, encouraging longer-term alignment with shareholders.
Arcturus Therapeutics Holdings Inc. filed an initial Form 3 for Chief Financial Officer Dennis Mulroy. The filing lists no reportable transactions or derivative positions, and no holdings entries are shown, serving purely as a baseline statement of beneficial ownership status.
Arcturus Therapeutics reported Q1 2026 revenue of $2.1 million, sharply down from $29.4 million a year earlier, mainly due to lower collaboration revenue from CSL Seqirus and reduced BARDA grant revenue. Net loss widened to $27.0 million, or $0.95 per share, from $14.1 million.
Operating expenses fell as research and development dropped to $21.5 million and general and administrative to $9.5 million, reflecting lower LUNAR‑COVID spending, BARDA activity, headcount and stock‑based compensation. Arcturus ended the quarter with $213.4 million in cash, cash equivalents and restricted cash and no debt, and believes this will fund operations for at least the next twelve months.
Clinically, the company advanced its rare‑disease RNA therapeutics: Phase 2 dosing progressed for cystic fibrosis candidate ARCT‑032 and enrollment continued in the Phase 2 OTC‑deficiency study ARCT‑810, with recent FDA feedback outlining steps toward a pivotal pediatric trial. Its partnered sa‑mRNA COVID‑19 vaccine KOSTAIVE gained UK marketing authorization, while collaboration partner CSL Limited recorded an approximately $430 million accounting write‑down related to the relationship, underscoring uncertainty around long‑term COVID‑19 vaccine demand and regulatory pathways.
Arcturus Therapeutics reported first quarter 2026 revenue of $2.1 million, down sharply from $29.4 million a year earlier, as it pivots from infectious disease vaccines toward rare disease programs. Total operating expenses fell to $31.0 million from $46.2 million, reflecting lower COVID-related manufacturing and trial costs.
The company posted a net loss of about $27.0 million, or ($0.95) per share, compared to a $14.1 million loss, or ($0.52) per share, in the prior-year quarter. Cash, cash equivalents and restricted cash were $213.4 million as of March 31, 2026, supporting a stated cash runway beyond the second quarter of 2028.
Arcturus initiated enrollment earlier than expected in a 12‑week open-label Phase 2 cystic fibrosis study and obtained FDA direction on the pediatric path for its ornithine transcarbamylase deficiency program ahead of an End of Phase 2 meeting in the second half of 2026. The company also appointed Dennis Mulroy as Chief Financial Officer, with a $520,000 base salary, up to 40% bonus eligibility, and options for 100,000 shares vesting over four years, plus severance and change‑in‑control protections.
Arcturus Therapeutics Holdings Inc. Schedule 13G/A shows ARK Investment Management LLC and Catherine D. Wood report beneficial ownership of 2,947,556 shares of Common Stock, representing 10.37% of the class. ARK holds sole voting and dispositive power over 2,947,556 shares; Catherine D. Wood holds shared voting and dispositive power over the same amount. Signatures dated 05/07/2026 appear on the amendment.
Arcturus Therapeutics Holdings Inc. is asking stockholders to vote at its fully virtual 2026 annual meeting on June 5, 2026 at 9:00 a.m. Pacific Time. Holders of 28,423,069 common shares as of April 14, 2026 can elect eight directors, approve on a non-binding advisory basis named executive officer compensation, and ratify Deloitte & Touche LLP as independent auditor for 2026. The meeting will be held online via https://www.cstproxy.com/arcturusrx/2026, with admission and voting procedures differing for registered and beneficial owners. The proxy explains quorum rules, broker non-votes, director independence, board committee structure, and outlines 2025 director fees and executive pay programs.